Introduction {#s1}
============

Corifollitropin alfa is the first hybrid molecule with sustained follicle-stimulating activity. Corifollitropin alfa is a recombinant fusion protein composed of FSH and the carboxy terminal peptide (CTP) of the hCG β-subunit ([@DEP291C12]). Like recombinant FSH (rFSH), corifollitropin alfa interacts only with the FSH-receptor and lacks LH activity ([@DEP291C20]; [@DEP291C13]). However, corifollitropin alfa has an approximately 2-fold longer elimination half-life (*t*~1/2~) and an almost 4-fold extended time-interval (*t*~max~) to peak serum levels (*C*~max~) ([@DEP291C11]). Due to this pharmacokinetic profile, corifollitropin alfa can function as a sustained follicle stimulant with a similar pharmacodynamic profile as rFSH, but with the ability to initiate and sustain multiple follicular growth for an entire week. Consequently, a single s.c. injection of the recommended dose of corifollitropin alfa can replace the first seven injections of any daily FSH preparation in an ovarian stimulation treatment cycle prior to IVF.

The need for simplified treatment approaches which will lessen the treatment burden of IVF is self-evident. The IVF treatment process itself is increasingly recognized as contributing to the physical, psychological and emotional burden on infertility patients ([@DEP291C3]; [@DEP291C6]). Infertile patients experience high levels of distress and their level of anxiety and depression is equivalent to that experienced by women with cancer or heart disease ([@DEP291C10]). A number of IVF studies in which treatment costs were reimbursed have nevertheless reported drop-out rates well above 50% before completing their covered number of cycles ([@DEP291C19]; [@DEP291C24]; [@DEP291C30]), largely due to the psychological impact of treatment ([@DEP291C25]; [@DEP291C29]). Thus, the primary reason for treatment discontinuation is not based on physician recommendation, but is because patients are too distressed to continue ([@DEP291C16]).

In GnRH antagonist co-treatment stimulation protocols, the duration of stimulation is reduced compared with GnRH agonist protocols and less FSH is used to reach the same criteria for administering hCG ([@DEP291C31]). Interestingly, a prospective cohort study comparing a GnRH antagonist protocol with a conventional long GnRH agonist protocol demonstrated a significantly reduced drop-out rate in the antagonist group, indicating that the impact of the treatment strategy is an important factor determining the risk of drop-out ([@DEP291C34]). Clearly, simple treatment regimens that lessen the burden of IVF improve the overall patient experience, and encourage lower drop-out rates ([@DEP291C23], [@DEP291C17], [@DEP291C28]). Last but not least, fewer injections to be given may improve drug compliance and/or prevent errors during drug administration.

Developing corifollitropin alfa in a short GnRH antagonist protocol may add to the further reduction of the treatment intensity experienced by patients undergoing ovarian stimulation for IVF. Following the dose-finding trial ([@DEP291C32]) and subsequent pharmacokinetic/pharmacodynamic modeling ([@DEP291C7]) it was concluded that the recommended dose of corifollitropin alfa was 100 µg for subjects with body weight of ≤60 kg and 150 µg for subjects with body weight of \>60 kg. Based on simulations, these two dosages of corifollitropin alfa will provide the same exposure and the same degree of ovarian response in the recommended body weight groups. After a single injection of corifollitropin alfa on menstrual cycle day 2 or 3, treatment may be continued with a daily dose of rFSH from stimulation day 8 onwards if needed. Patients who reach the criteria of triggering final oocyte maturation prior to day 8 of stimulation do not require any daily FSH to be administered.

First and foremost the question that needs to be addressed is whether the new corifollitropin alfa regimen results in the same success rates as a daily FSH regimen with GnRH antagonist co-treatment. To this end, the aim of the ENGAGE trial was to investigate whether the ongoing pregnancy rates of the new corifollitropin alfa regimen were comparable to a daily rFSH regimen in patients undergoing ovarian stimulation prior to IVF. The sample size required to sufficiently power this trial for ongoing pregnancy rate as a primary end-point renders this the largest double-blind randomized trial in the field of assisted reproductive technology (ART) to date.

Materials and Methods {#s2}
=====================

The ENGAGE trial was a multi-center, randomized, double-blind double-dummy, non-inferiority clinical trial involving 14 centers in North America (13 centers in USA and one in Canada) and 20 centers in Europe (three in Spain and The UK; two in Belgium, Czech Republic, Finland, France, Norway, and Sweden; one in Denmark and The Netherlands) and conducted between June 2006 and January 2008.

The study was approved by the Independent Medical Ethics Committee or Institutional Review Board for each center as well as by the responsible Health Authority and was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonization guidelines for Good Clinical Practice, and local regulatory requirements. An Independent Data Safety Monitoring Board was appointed to monitor the safety of subjects participating in the trial, and written informed consent was provided by all patients.

Study population {#s2a}
----------------

Women aged 18--36 years with a body weight of more than 60 kg up to and including 90 kg, a BMI of 18--32 kg/m^2^, a menstrual cycle length of 24--35 days, access to ejaculatory sperm and an indication for controlled ovarian stimulation (COS) before IVF or ICSI were eligible to enroll in the study. Patients who had a (history of) an endocrine abnormality, an abnormal outcome of blood biochemistry or hematology, an abnormal cervical smear, a chronic disease, relevant ovarian-, tubal- or uterine-pathology that could interfere with the COS treatment (e.g. endometrioma \>0 mm or fibroids ≥5 cm), embryo implantation or pregnancy were not to be included in the trial. Patients who had a history of ovarian hyperresponse (more than 30 follicles ≥11 mm) or ovarian hyperstimulation syndrome (OHSS), polycystic ovary syndrome (PCOS) or a basal antral follicle count (AFC) of more than 20 on ultrasound (\<11 mm, both ovaries combined) were excluded from participation. Other exclusion criteria included a previously low ovarian response to FSH or hMG treatment (i.e. cycle cancelled due to insufficient ovarian response or less than four oocytes obtained), an FSH or LH over 12 IU/L in the early follicular phase, more than three consecutive unsuccessful IVF cycles since the last ongoing pregnancy, a history of recurrent miscarriage (three or more), or currently smoking more than five cigarettes per day.

Study design {#s2b}
------------

The trial was designed as a randomized, double-blind, double-dummy, active-controlled, non-inferiority trial to compare the efficacy of a single injection of corifollitropin alfa during the first week of stimulation with 7 daily injections of rFSH for inducing and sustaining multifollicular growth during COS. Randomization to one of the two treatment arms (1:1 ratio) was done per center and stratified by age (\<32 and≥32 years) by central remote allocation using randomly permutated blocks with an undisclosed fixed block size of four.

Stimulation regimen and ART procedures {#s2c}
--------------------------------------

All patients were to start their treatment cycle on menstrual cycle day 2 or 3 as depicted in Fig. [1](#DEP291F1){ref-type="fig"}. Per protocol all injections were to be administered in the morning. Patients started stimulation with a single s.c. injection of 150 µg (0.5 mL) corifollitropin alfa (NV Organon, The Netherlands) or matching placebo. Injections could be done by the patient herself, her partner or the medical staff. To conceal treatment allocation all patients also started daily s.c. injection of 200 IU rFSH (follitropin beta, Puregon^®^/Follistim^®^ AQ Cartridge, NV Organon, The Netherlands) or matching placebo on the same day (Stimulation Day 1) using the Puregon^®^/Follistim Pen^®^. Daily active or placebo ('dummy') rFSH injections were continued through the first 7 days of stimulation. The chosen reference dose of 200 IU rFSH daily was considered the optimal choice for the included patient population weighing over 60 kg in a global trial combining European and North American sites. This dose was fixed for the first 5 days of stimulation. This is in line with the suggestion by [@DEP291C2]) who recommended a fixed starting dose for at least 5--7 days in all efficacy trials as only after such period the impact of the administered FSH dose can be adequately evaluated. Moreover, this is considered appropriate because daily FSH only reaches steady state after 3--5 days of dosing ([@DEP291C21]). A reduction of the rFSH dose was allowed from stimulation day 6 onward in case of too high an ovarian response, at the discretion of the investigator. When no follicle ≥11 mm was visible on ultrasound scan (USS) before injection on stimulation day 8 the cycle was to be cancelled due to insufficient ovarian response. From stimulation day 8 onwards, treatment in both groups was continued with a daily s.c. dose of (active) rFSH up to and including the day of hCG administration. The maximum rFSH dose to continue treatment after the first 7 days was 200 IU but the dose could be reduced when desired. For normal responders, the recommended daily dose of rFSH was 150 IU. Whenever deemed required by the investigator, rFSH administration could be withheld for a maximum of 3 days (coasting) up to and including the day of hCG administration. In case there was a too high ovarian response as per the investigator\'s opinion, the cycle could be cancelled at any time. However, in case of a risk for OHSS, defined as more than 30 follicles of ≥11 mm on USS, hCG was always to be withheld and the treatment cycle was to be cancelled per protocol. The maximum total duration of stimulation was 19 days.

![Graphical illustration of the treatment regimens applied in this trial. Upper panel depicts investigational group (corifollitropin alfa), lower panel depicts reference group (rFSH).\
rFSH: recombinant FSH, P: progesterone.](dep29101){#DEP291F1}

To prevent premature LH surges the GnRH antagonist ganirelix (0.25 mg, Orgalutran^®^/ganirelix acetate injection, NV Organon, The Netherlands) was administered once daily s.c. starting on stimulation day 5 up to and including the day of hCG. Urinary hCG (10 000 IU) was administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed by USS. Investigators were allowed to delay hCG administration for 1 day when preferred for practical reasons. In case there was a too high ovarian response in the opinion of the investigator, a lower dose (5000 IU hCG) could be used. About 34--36 h thereafter, oocyte retrieval followed by standard IVF or ICSI was to be performed. Embryo quality was evaluated for all available embryos on day 3 of culture by the local embryologist using a protocol-defined guideline based on the following parameters: number of blastomeres, degree of fragmentation, blastomere size uniformity and presence or absence of multinucleation. Embryos graded as grade 1 (6--10 cells, no fragmentation and equal blastomere size) or grade 2 (allowing up to 20% fragmentation) were qualified as good quality embryos. The quality of embryos continued in culture after day 3 was reassessed on the day of transfer or freezing using grading criteria appropriate for the stage of embryo culture. At embryo transfer, 3 or 5 days after oocyte retrieval, one or two embryos were to be transferred. The decision on the day of transfer and number of embryos to be transferred was made by the investigator. To support implantation and early pregnancy, luteal phase support with progesterone (at least 600 mg/day vaginally or at least 50 mg/day i.m., to be prescribed locally) was started on the day of oocyte retrieval and continued for at least 6 weeks, or either up to menses or up to a negative pregnancy test performed at least 14 days after embryo transfer.

Assessments {#s2d}
-----------

Before the start of ovarian stimulation, pregnancy was excluded by means of an hCG test, a blood sample was obtained for hormone assessments, and USS was performed to measure and count visible follicles. Local tolerance parameters (pain, itching, swelling and redness) were assessed by the clinical staff 30 min after injection for both (placebo) corifollitropin alfa and (placebo) rFSH injection sites. Patients returned to the clinic for USS and blood sampling on stimulation days 5 and 8, and then daily up to and including the day of hCG administration for USS only. Additional blood samples were collected on the day of embryo transfer and 2 weeks after embryo transfer. Patients who left the study prior to embryo transfer were sampled for hormones and antibody assessments at the day of discontinuation and 2 weeks thereafter.

Validated immunoassays were performed at a central laboratory (Schering-Plough, Oss, The Netherlands and Waltrop, Germany) to measure serum levels of FSH, LH, estradiol (E~2~), progesterone, inhibin-B and antibodies against corifollitropin alfa ([@DEP291C9]).

End-points {#s2e}
----------

Ongoing pregnancy, defined as presence of at least one fetus with heart activity at least 10 weeks after embryo transfer as assessed by USS or Doppler, or confirmed by live birth, was the primary end-point for this trial. This can be considered as the best and closest estimate of the ultimate treatment success (delivery of a healthy baby) and excludes subjects with a miscarriage during the first 10 weeks of pregnancy ([@DEP291C2]). In addition, the number of retrieved oocytes was considered as co-primary end-point in this trial being more proximately related to the pharmacological effect of the two treatment regimens which are compared in this trial. Other clinical outcome parameters evaluated included dose of rFSH required, duration of stimulation, number and size of follicles, serum hormone levels, fertilization rate, number and quality of embryos obtained and pregnancy rates. The ultimate live birth rate, the health of the offspring, and outcomes achieved with spare, frozen embryos will be reported separately when follow-up has been completed.

Occurrence of (serious) adverse events, including moderate and severe OHSS as per World Health Organization criteria ([@DEP291C37]), outcome of local tolerance and immune response assessments were evaluated as safety end-points.

Statistical analysis {#s2f}
--------------------

The sample size needed for this trial was largely determined by the chosen pre-defined non-inferiority margin (i.e. smaller margin requires larger sample size to maintain the same power) but also depended on the anticipated ongoing pregnancy rate (i.e. higher pregnancy rate requires larger sample size) to be expected in a combined trial comprising sites in Europe, USA and Canada. For this global trial a non-inferiority margin of 8% was considered appropriate. This implies that if the lower bound of the 95% confidence interval (CI) for the estimated difference in ongoing pregnancy rates between treatment groups (corifollitropin alfa minus rFSH) was determined to be above −8%, corifollitropin alfa could be considered non-inferior to rFSH. Although such a difference would be relevant for an individual subject seeking to become pregnant after IVF treatment it should be considered in the context of existing differences in routine pregnancy rates between centers, countries and regions ([@DEP291C14], [@DEP291C15]). A sample size of at least 1380 subjects was calculated to be the minimum required to demonstrate non-inferiority with a power of 90%, using a −8% non-inferiority margin for the lower limit of the two-sided 95% CI, and assuming an ongoing pregnancy rate of 30%. Based on these data, a minimum of 700 subjects per group, in total at least 1400 subjects, were to be randomized which makes this the largest double-blind comparative randomized trial performed to date.

For analysis of the primary end-point, ongoing pregnancy, the treatment groups were formally compared with a generalized linear model for the ongoing pregnancy rate including covariates treatment group, age (\<32 years, ≥32 years) and region (Europe, North America). The difference between the two treatment groups (corifollitropin alfa − rFSH) and its associated two-sided 95% likelihood-based CI was estimated and a pre-defined non-inferiority margin of 8% was applied. Additional explorative analyses were performed to investigate robustness of the primary end-point results. No adjustment for multiplicity to correct for repeated testing was performed.

The number of cumulus--oocyte-complexes retrieved was defined as co-primary end-point in this trial. As there is an optimal range of oocytes obtained in response to ovarian stimulation, below and above which the success rates of IVF are compromised ([@DEP291C33]) equivalence testing was deemed appropriate. Therefore, equivalence margins for the difference in the number of oocytes retrieved were predefined to be −3 and +5 oocytes. If the new corifollitropin alfa regimen resulted in three or more oocytes less than the reference treatment, such difference was considered as clinically relevant because three oocytes usually result in one good quality embryo for transfer or freezing. Anticipating obtaining an average of 12--13 oocytes with the applied rFSH doses in the reference group, an excess of more than five oocytes would be undesirable as patients with more than 18 oocytes retrieved are described to be at increased risk of developing OHSS ([@DEP291C27]; [@DEP291C35]). Hence, an upper margin of +5 oocytes is applied for the difference in the number of oocytes retrieved between the treatment groups. The treatment groups were formally compared using analysis of variance for the number of oocytes including covariates treatment group, age (\<32 years versus ≥32 years) and center. The estimate of the difference between the two treatment groups and its associated two-sided 95% CI was given. In case the 95% CI of the difference exceeded −3 or +5 oocytes corifollitropin alfa treatment was not considered equivalent to the rFSH treatment.

Efficacy analyses are based on the intention-to-treat (ITT) population entailing all patients randomized and treated, analyzing them according to their allocated treatment (i.e. 'as randomized'). Both ITT and per protocol (PP) analyses were performed (see [Supplementary Data](http://humrep.oxfordjournals.org/cgi/content/full/dep291/DC1)), but as the results were very similar, only the ITT results are presented here. The main efficacy analyses were performed 'per started cycle' (i.e. including all subjects who started treatment regardless whether they discontinued) as this provides the most conservative efficacy estimates as it also accounts for any unintended interference of premature cycle cancellations. For safety end-point analyses, patients are grouped 'as treated' which implied that three patients (one randomized to corifollitropin alfa and two patients to rFSH) treated inadvertently with the wrong (comparator) medication type are analyzed according to the treatment they actually received. Statistical significance was set at *P* \< 0.05.

Results {#s3}
=======

A total of 1696 patients signed informed consent for eligibility evaluation and participation in this trial (Fig. [2](#DEP291F2){ref-type="fig"}). Subsequently a total of 187 patients failed screening or dropped out due to personal reasons prior to treatment allocation. Eventually, 1509 patients were randomized to one of the two treatment groups of which 1506 patients actually started stimulation. The remaining three patients were discontinued prior to the start of treatment (one for personal reasons and two were found to violate entry criteria after randomization but before commencing treatment).

![Flow chart showing the number of participants at each stage of the clinical trial.](dep29102){#DEP291F2}

Demographics of the ITT population as well as relevant fertility characteristics, USS findings and hormone profiles were comparable in the two groups (Table [I](#DEP291TB1){ref-type="table"}). Mean age (SD) of the patients included in this trial was 31.5 (3.3) years, body weight was 68.6 (7.5) kg and BMI was 24.8 (2.7) kg/m^2^. The average duration of infertility was 3.3 (2.3) years and for 74% of the patients this was their first treatment cycle. On stimulation day 1, no differences were observed between the treatment groups in the basal AFC or baseline serum hormone levels (Table [I](#DEP291TB1){ref-type="table"}).

###### 

Demographics, fertility characteristics and baseline (stimulation day 1) ultrasound scan (USS) and serum hormone levels per treatment group (intent-to-treat population)

                                      Corifollitropin alfa (*n* = 756)   rFSH (*n* = 750)
  ----------------------------------- ---------------------------------- ------------------
  Demographics                                                           
   Age (years)                        31.5 (3.3)                         31.5 (3.2)
   Body weight (kg)                   68.8 (7.6)                         68.4 (7.3)
   BMI (kg/m^2^)                      24.8 (2.8)                         24.8 (2.7)
  Race, *n* (%)                                                          
    Asian                             21 (2.8)                           21 (2.8)
    Black                             33 (4.4)                           28 (3.7)
    Caucasian                         643 (85.1)                         650 (86.7)
    Other                             59 (7.8)                           51 (6.8)
  Fertility characteristics                                              
   Primary infertility, *n* (%)       403 (53.3)                         393 (52.4)
   Duration of infertility (years)    3.3 (2.4)                          3.2 (2.2)
  Cause of infertility^a)^, *n* (%)                                      
    Male factor                       388 (51.3)                         347 (46.3)
    Tubal factor                      198 (26.2)                         191 (25.5)
    Endometriosis                     109 (14.4)                         115 (15.3)
    Other/unexplained                 246 (32.5)                         262 (34.9)
   First IVF cycle, *n* (%)           569 (75.3)                         552 (73.6)
  Stimulation day 1                                                      
   Total ovarian volume (mL)^b)^      13.2 (8.1)                         13.2 (7.1)
   Basal AFC (\<11 mm)                12.3 (4.6)                         12.4 (4.4)
   FSH (IU/L)                         6.7 (2.1)                          6.6 (1.9)
   LH (IU/L)                          4.8 (2.0)                          4.7(1.8)
   E~2~ (pmol/L)                      126.1 (39.3)                       124.8 (37.4)
   Progesterone (nmol/L)              1.8 (1.3)                          1.8 (1.4)

AFC: antral follicle count, E~2~: estradiol, rFSH: recombinant FSH.

Numbers are mean (SD) unless otherwise indicated.

^a)^A patient can have multiple causes of infertility.

^b)^According to the formula for a polate ellipsoid: 0.523 × longitudinal × antero-posterior × transverse diameters as measured per transvaginal ultrasound.

Primary end-point: ongoing pregnancy rate {#s3a}
-----------------------------------------

Results of the primary end-point analyses are presented in Table [II](#DEP291TB2){ref-type="table"}. High ongoing pregnancy rates of 38.9% for the corifollitropin alfa group and 38.1% for the rFSH group were obtained per started cycle. The estimated treatment difference, adjusted for age group (\<32 years, ≥32 years) and region (Europe, North America), was +0.9% \[95% CI: (−3.9; 5.7)\] in favor of corifollitropin alfa.

###### 

Primary end-points of the ENGAGE trial: ongoing pregnancy rate (assessed at least 10 weeks after embryo transfer) and the mean (SD) number of cumulus--oocyte-complexes retrieved (intent-to-treat population)

                              Corifollitropin alfa (*n* = 756)   rFSH (*n* = 750)   Estimated difference^a)^ \[95% CI\], *P*-value
  --------------------------- ---------------------------------- ------------------ ------------------------------------------------
  Ongoing pregnancies (*n*)   294                                286                
   Per started cycle (%)      38.9%                              38.1%              0.9 \[−3.9; 5.7\], *P* = 0.71
   Per embryo transfer (%)    43.8%                              40.6%              3.1 \[−2.0; 8.2\], *P* = 0.24
  Cumulus--oocyte-complexes                                                         
   Per started cycle          13.7 (8.2)                         12.5 (6.7)         1.2 \[0.5; 1.9\], *P* = 0.001
   Per oocyte retrieval       14.1 (7.9)                         12.7 (6.7)         1.6 \[0.8; 2.3\], *P* \< 0.001

*P*-value corresponds to the test whether the treatment difference equals zero.

^a)^Estimated treatment difference (corifollitropin alfa − rFSH) adjusted for covariates.

Co-primary end-point: number of cumulus--oocyte-complexes retrieved {#s3b}
-------------------------------------------------------------------

The number of cumulus--oocyte-complexes retrieved was defined as co-primary end-point in this trial. The mean (SD) number of oocytes retrieved in the corifollitropin alfa group was 13.7 (8.2) which was higher than the mean of 12.5 (6.7) obtained in the rFSH group (Table [II](#DEP291TB2){ref-type="table"}). The estimated treatment difference was 1.2 oocytes in favor of corifollitropin alfa (*P* = 0.001), while the 95% CI was (0.5; 1.9). This indicates that the number of oocytes retrieved in the two treatment groups was at least equivalent based on the pre-defined equivalence range.

Other clinical outcome parameters {#s3c}
---------------------------------

The median duration of stimulation was 9 days for both treatment groups, which implied patients treated with corifollitropin alfa needed on average 2 days of rFSH to complete their treatment cycle (Table [III](#DEP291TB3){ref-type="table"}). Per protocol, the dose of (placebo) rFSH could be reduced (not increased) from stimulation day 6 onwards. Dose decreases on stimulation days 6 or 7 were recorded slightly more often in the corifollitropin alfa group (85/750, 11.3%) than in the rFSH group (62/741, 8.4%). Coasting by withholding rFSH for 2 or more days was applied in 1.6% \[12/733, 95% CI: (0.7; 2.6)\] of patients in the corifollitropin alfa group and in 2.2% \[16/741, 95% CI: (1.0; 3.3)\] of patients in the rFSH group. A fixed dose regimen from stimulation day 8 up to but not including the day of hCG was used in 72.1% (413/573) of the corifollitropin alfa group and 81.0% (430/531) of the rFSH group. After a single injection of corifollitropin alfa, 249 out of 756 patients (32.9%) reached the criteria for giving hCG before or on stimulation day 8: the ongoing pregnancy rate for this subgroup of patients was 44.0%.

###### 

Clinical parameters from stimulation phase up to embryo transfer (intent-to-treat population)

                                                   Corifollitropin alfa (*n* = 756), median (range)   rFSH (*n* = 750), median (range)
  ------------------------------------------------ -------------------------------------------------- ----------------------------------
  Stimulation characteristics^a)^                                                                     
   Total dose of rFSH (IU)                         400 (0--2000)                                      1800 (400--2800)
   Total dose of rFSH from day 8 onwards (IU)      400 (0--2000)                                      400 (0--1400)
   Total duration of stimulation (days)^b)^        9 (6--18)                                          9 (6--15)
  Follicles, day of hCG^a)^                                                                           
   ≥11 mm                                          16.0 (7.0)                                         13.9 (6.1)
   ≥15 mm                                          9.6 (4.8)                                          8.7 (4.0)
   ≥17 mm                                          5.7 (3.2)                                          5.6 (2.9)
  Serum parameters, day of hCG^a)^                                                                    
   FSH (IU/L)                                      12.5 (3.3)                                         11.6 (2.8)
   LH (IU/L)                                       1.4 (1.8)                                          1.9 (1.6)
   E~2~ (pmol/L)                                   5508.8 (3469.8)                                    5165.3 (2998.2)
   Inhibin-B (pg/mL)                               610.3 (492.3)                                      614.8 (435.6)
   Progesterone (nmol/L)                           3.0 (2.1)                                          3.2 (1.5)
  Clinical outcome per started cycle                                                                  
   Oocytes retrieved, ICSI only                    13.8 (7.6)                                         12.1 (6.3)
   Metaphase II oocytes (ICSI only), % of total    10.8 (6.5), 78.9 (18.9)                            9.2 (5.1), 77.4 (18.1)
   Fertilization rate (%)^c,d)^                    66.0 (23.4)                                        67.6 (22.9)
   Total number of embryos obtained (day 3)^c)^    8.3 (5.6)                                          7.4 (4.8)
   Excellent (top) quality embryos (grade 1)^c)^   2.6 (3.4)                                          2.5 (3.4)
   Good quality embryos (grade 1+2)^c)^            4.6 (4.3)                                          4.4 (3.9)
   Single embryo transfer (%)^d)^                  25.7                                               27.0
   Embryos transferred^e)^                         1.7 (0.4)                                          1.7 (0.4)
   Embryos cryopreserved^f)^                       4.3 (3.6)                                          3.9 (2.7)

Numbers are mean (SD) unless otherwise indicated.

^a)^Restricted to patients with hCG injection.

^b)^Number of days up to and including the day of hCG administration.

^c)^Restricted to patients with IVF and/or ICSI.

^d)^Defined as 100 times the number of mature oocytes (with two pronuclei) obtained divided by the number of oocytes used for fertilization.

^e)^Restricted to patients with embryo transfer.

^f)^Restricted to patients with cryopreserved embryos.

Eventually, 97.0% of the patients in the corifollitropin alfa group and 98.8% of the rFSH group received hCG to induce final oocyte maturation. The vast majority received 10 000 IU hCG (76.9% (581/756) and 85.6% (642/750) of the patients in the corifollitropin alfa and rFSH group, respectively), while a dose of 5000 IU hCG was used for 19.8% (150/756) and 13.1% (98/750) of the respective groups. Only the most frequent reasons for discontinuation *prior to hCG* are mentioned. In total, 23 (3.0%) of the patients in the corifollitropin alfa group and 7 (0.9%) of the patients in the rFSH group discontinued prior to hCG. In the rFSH group, 2 patients discontinued after the oocyte retrieval procedure, but it appeared that they had not received hCG. Taking this into account, totals add up correctly to the number of subjects treated with hCG (733 = 756−23, 741 = 750−7−2).

On the day of hCG, the mean (SD) number of follicles measuring ≥11 mm on USS was 16.0 (7.0) for the corifollitropin alfa group and 13.9 (6.1) for the rFSH reference group (Table [III](#DEP291TB3){ref-type="table"}). When comparing serum hormones on the day of hCG administration comparable levels were observed in both treatment groups. Oocyte retrieval was performed in 96.8% of the patients in the corifollitropin alfa group and 98.9% in the rFSH group. A higher mean number of cumulus--oocyte-complexes was retrieved in the corifollitropin alfa group (Table [II](#DEP291TB2){ref-type="table"}). Oocyte maturity was assessed for ICSI patients and also showed a higher number and percentage of mature oocytes (Table [III](#DEP291TB3){ref-type="table"}) in the corifollitropin alfa group (mean 10.8, 78.9%) compared with the rFSH group (mean 9.2, 77.4%). A comparable fertilization rate was observed between the groups resulting in a mean (SD) of 8.3 (5.6) embryos obtained on day 3 of culture in the corifollitropin alfa group and 7.4 (4.8) embryos in the rFSH group for patients with IVF and/or ICSI. Embryo quality, as assessed by the local embryologist, was similar in both groups.

Ultimately, 672 patients (88.9%) in the corifollitropin alfa group and 704 patients (93.9%) in the rFSH group had embryo transfer in this trial. Between hCG administration and embryo transfer 39 out of 756 patients (5.2%) in the corifollitropin alfa group and 34 out of 750 (4.5%) patients in the rFSH group were discontinued as a result of too few or too low quality oocytes, lack of fertilization or poor embryo development. During this period 6/756 patients (0.8%) in the corifollitropin alfa group and none in the rFSH group were discontinued due to a too high ovarian response or risk of OHSS. Although no embryo transfer was performed, fertilized oocytes or embryos were cryopreserved for all these six patients. When embryo transfer was performed, single embryo transfer was carried out in slightly more than a quarter of all transfers (Table [III](#DEP291TB3){ref-type="table"}). On average, 1.7 (0.4) embryos were transferred in both treatment groups. For 51.7 and 53.2% of the patients in the corifollitropin alfa and rFSH groups, a mean (SD) of 4.3 (3.6) and 3.9 (2.7) supernumerary embryos have been cryopreserved, respectively.

In the corifollitropin alfa group 29.2% (221/756), and in the rFSH group 30.3% (227/750), received only i.m. luteal phase progesterone support, whereas respectively 52.0% (393/756) and 54.9% (412/750) received only intravaginal progesterone support. Other subjects received a combination of routes.

Pregnancy rates (confirmed by positive hCG test) of 48.1 and 46.9% were achieved in the corifollitropin alfa and rFSH groups, respectively, followed by a comparable number of early pregnancy losses during the first 10 weeks after embryo transfer. Accordingly, similar ongoing pregnancy rates were observed in both groups (Table [IV](#DEP291TB4){ref-type="table"}). There was no relevant difference in the ongoing pregnancy rates between subjects who received the hCG injection on the same day that three follicles ≥17 mm were observed (40.0 and 37.8% for corifollitropin alfa and rFSH, respectively) versus subjects who received hCG one day later (38.9 and 41.8% for corifollitropin alfa and rFSH, respectively).

###### 

Clinical efficacy outcomes per started cycle (intent-to-treat population)

                                    Corifollitropin alfa (*n* = 756)   rFSH (*n* = 750)   *P*-value^a)^
  --------------------------------- ---------------------------------- ------------------ ---------------
  Positive hCG test^b)^, *n* (%)    364 (48.1)                         352 (46.9)         0.64
  Clinical pregnancy^c)^, *n* (%)   322 (42.6)                         308 (41.1)         0.57
  Vital pregnancy^d)^, *n* (%)      302 (39.9)                         293 (39.1)         0.75
  Ongoing pregnancy^e)^, *n* (%)    294 (38.9)                         286 (38.1)         0.71
  Multiple pregnancy^f)^, *n* (%)   83 (28.2)                          66 (23.1)          0.18
  Early miscarriage^g)^, *n* (%)    27 (8.4)                           21 (6.8)           0.55

^a)^*P*-values are based on Fisher\'s exact test, except for ongoing pregnancy where the *P*-value is based on the likelihood ratio test corresponding to the generalized linear model with covariates treatment group, age class (\<32 years, ≥32 years) and region (Europe, North America).

^b)^Positive hCG test at least 14 days after embryo transfer or USS with at least one gestational sac.

^c)^Clinical pregnancy: gestational sac on USS.

^d)^Vital pregnancy: gestational sac + fetal heartbeat.

^e)^Ongoing pregnancy: vital fetus at least 10 weeks after embryo transfer or live birth.

^f)^Per ongoing pregnancy.

^g)^Per clinical pregnancy.

The robustness of this primary efficacy outcome was explored in specific subsets of patients grouped according to the ART procedure-related factors, i.e. undergoing IVF or ICSI, having single or double embryo transfer and having embryo transfer on day 3 or day 5 (Fig. [3](#DEP291F3){ref-type="fig"}). The ongoing pregnancy rates in each subset were similar for corifollitropin alfa and rFSH and there was no significant interaction with the type of treatment factor (IVF or ICSI), nor for the number of embryos transferred (one or two). A borderline significant interaction with the type of treatment was only observed for the factor day of transfer (*P* = 0.045) as a result of higher pregnancy rates for day 3 transfers with corifollitropin alfa whereas, for day 5 transfers, the rFSH group showed marginally higher pregnancy rates (Fig. [3](#DEP291F3){ref-type="fig"}). The subset analyses together confirm the robustness of the observed difference in pregnancy rates, independent of ART procedure-related parameters.

![Ongoing pregnancy rates stratified for fertilization procedure, number of embryos transferred and day of transfer. Subset with double embryo transfer includes three patients with three embryos transferred.](dep29103){#DEP291F3}

Multiple pregnancy rates per ongoing pregnancy were 28.2% and 23.1% in the corifollitropin alfa group and the rFSH group, respectively (Table [IV](#DEP291TB4){ref-type="table"}). Although this difference is not significant, it is in line with the slightly higher implantation rate defined as 100 times the maximum number of gestational sacs divided by the number of embryos transferred per subject for corifollitropin alfa \[observed means (SD) were 36.2% (41.6%) versus 32.2% (40.1%)\].

Safety {#s3d}
------

In total, 16 subjects (2.1%) in the corifollitropin alfa group discontinued due to a (serious) adverse event \[SAE, two (0.3%) before and 14 (1.9%) following oocyte retrieval\] as compared with three subjects (0.4%) in the rFSH group \[two (0.3%) before and one (0.1%) after oocyte retrieval\]. A total of 53 patients in the corifollitropin alfa-treated group (7.0%) and 47 patients in the rFSH-treated group (6.3%) developed OHSS in this trial. The incidences of (moderate/severe) OHSS were 4.1% \[31/755, 95% CI: (2.6; 5.6)\] and 2.7% \[20/750, 95% CI: (1.5; 3.9)\] for the corifollitropin alfa and rFSH group, respectively, which was not significant (Fisher exact *P* = 0.15).

An equal number of 37 SAEs was reported for the corifollitropin alfa and the rFSH-treated groups. Most frequently reported SAEs were OHSS \[14 patients (1.9%) treated with corifollitropin alfa and 9 patients (1.2%\] treated with rFSH) and (ruptured) ectopic pregnancy \[7 patients (0.9%) and 9 patients (1.2%), respectively\] while, respectively, the most frequently reported AEs were procedural pain (22.3 and 20.1%), pregnancy-related events including (missed) abortion (13.8 and 11.2%), pelvic pain (12.1 and 12.3%), pelvic discomfort (11.5 and 11.6%) and headache (10.5 and 15.2%). There were no drug-related immune responses or moderate or severe local tolerance reactions observed in this trial.

Discussion {#s4}
==========

The current ENGAGE trial was a double-blind, double-dummy trial initiated to investigate whether the new corifollitropin alfa regimen provides similar success rates compared with the current care. The double-dummy approach guaranteed the blinding of medication during the trial and prevented any bias in terms of treatment decisions. Owing to the fact that the trial was powered to enable comparison of the ongoing pregnancy rates as the primary study end-point, this is the largest double-blind efficacy trial in IVF performed to date. The outcome of the trial provides compelling evidence of equal efficacy in terms of ongoing pregnancy rates, because the point estimates i.e. 38.9 and 38.1% for the ongoing pregnancy rates were very close for the two treatment groups and the 95% lower limit of the difference was only −3.9%. Subset analyses of subjects undergoing IVF or ICSI and of subjects who had single or double embryo transfer reveal consistently high ongoing pregnancy rates, similar between the treatment groups, which confirm the robustness of the primary end-point. Even though an equal number and quality of embryos were replaced in both treatment groups, the multiple pregnancy rate in the corifollitropin alfa group tended to be higher (+4.4% absolute risk increase) than in the reference group, which may be related to the slightly higher implantation rate. This increase, although not significant, cannot be ruled out and may prove to be clinically relevant, given the low power of the study to detect such a difference (*c*.22%). In this context, it should be emphasized that both treatment arms used a 'protocolized' fixed dose treatment regimen applying GnRH antagonist (ganirelix) co-treatment, which confirms the successful outcome of a patient-friendly short GnRH antagonist protocol in corifollitropin alfa, as well as rFSH, treatment cycles. In addition, one-third of the patients treated with a single injection of corifollitropin alfa reached the criteria for hCG injection prior to or on stimulation day 8, omitting the need for any additional FSH injections. The ongoing pregnancy rate of this subset of good responder patients was 44.0%, thus 5.9% higher than the overall group of subjects treated with corifollitropin alfa.

A hybrid molecule composed of human FSH and the CTP of hCG was first described by Boime and colleagues ([@DEP291C12]). In subsequent clinical trials the new recombinant fertility hormone exhibited a slower absorption (and subsequent rise to peak levels) and an approximately 2-fold longer *t*~1/2~ compared with rFSH ([@DEP291C4]; [@DEP291C11]). After corifollitropin alfa injection, peak levels of FSH activity are reached within 2 days whereas steady state levels with daily FSH are reached only after 4--5 days ([@DEP291C22]). These pharmacokinetic properties of corifollitropin alfa create an opportunity to further simplify ovarian stimulation protocols for IVF by omitting the need for daily gonadotrophin injections during the first week of stimulation ([@DEP291C13]). In the current trial, the difference in exposure during the first days of stimulation may have resulted in a slightly higher ovarian response in the corifollitropin alfa treated patients, as previous trials with rFSH have shown that the number of follicles recruited increases with the starting dose of rFSH given ([@DEP291C36]; [@DEP291C26]). In view of the equal pregnancy rates, the current trial does not suggest that the higher exposure to FSH immunoactivity during the first days of stimulation interferes with the endometrial receptivity.

In this trial hormonal pretreatment with oral contraceptives or supplementation with LH or hCG during the treatment phase was not allowed per protocol. The efficacy results in this large, global, multi-center trial suggest that the amount of endogenous LH during treatment with either corifollitropin alfa or daily rFSH in a standard GnRH antagonist protocol is sufficient to support high success rates in terms of ongoing pregnancies ([@DEP291C5]).

Because of concerns that the relatively high exposure to corifollitropin alfa during the first days of stimulation might initiate an early rise of LH ([@DEP291C9]), all patients in this trial started treatment with ganirelix on stimulation day 5. This fixed start of GnRH antagonist co-treatment was considered advantageous from an efficacy perspective as this may result in higher pregnancy rates, as well as from a methodological point of view as this reduces variability in the applied treatment regimens ([@DEP291C18]; [@DEP291C1]; [@DEP291C2]).

The corifollitropin alfa regimen used in this trial comprised a single dose of corifollitropin alfa followed by daily doses of rFSH (as needed up to a daily maximum of 200 IU). This corifollitropin regimen was compared with a fixed dose of 200 IU/day rFSH for the first 7 days, but with the option to decrease the daily FSH dose in cases when hyper-response was observed. Thus there was a difference in patient management options, with no option to adjust the dosing during the first week of stimulation in the corifollitropin arm. After corifollitropin alfa injection, serum FSH activity declines from stimulation day 3 (*C*~max~) onwards, but further reduction of exposure during the first week of stimulation cannot be attained.

The validity of the claimed efficacy and safety data of this trial are limited to the study population only. Patients with known risk factors for a hyper-response, such as patients with a history of OHSS, with PCOS or with a high AFC (\>20) were excluded from the current trial. In addition, patients with a history of low ovarian response in a previous IVF cycle were excluded. However, it should be noted that 74% of the patients included in this trial underwent their first IVF cycle for which the ovarian response is less predictable and will still include low- and high responder patients.

In this large cohort of (potential) normal responder patients, corifollitropin alfa has been shown to be well tolerated and non-immunogenic. In line with the higher ovarian response, the observed incidence of OHSS was higher in the corifollitropin alfa group, but the difference was not significant. Our study was not sufficiently powered to detect an underlying difference in the incidence of OHSS, and therefore its actual presence cannot be excluded. In line with the recruitment of slightly more follicles by corifollitropin alfa, dose reductions during stimulation were more frequently made in the corifollitropin alfa group than in the reference group. Clearly, a minority of subjects required a dose reduction on stimulation day 6 or 7, which may have affected the ovarian response in the rFSH group rather than in the corifollitropin alfa group in which only the placebo was reduced.

Appropriate clinical monitoring and lowering or withholding the daily rFSH dose to complete the cycle, as well as lowering or withholding the dose of hCG to trigger final oocyte maturation, or cryopreservation of all embryos obtained are options which can be considered as part of patient management to minimize the risk of OHSS ([@DEP291C8]).

Owing to the double-blind design of the trial, requiring all patients to be treated with an equal number of injections, no comparative data could be collected on perceived patient convenience or preference for the corifollitropin alfa regimen. Since a single injection of corifollitropin alfa replaces the first seven daily injections of rFSH during ovarian stimulation, the intuitive advantages of such a simpler treatment regimen are obvious, but need to be confirmed in clinical practice. In addition to patient preference, future controlled trials may examine the efficacy of corifollitropin alfa in (potential) poor responding patients as well as the safety in (potential) high responders.

In conclusion, in this study we tested the efficacy (in terms of ongoing pregnancy rates) of substituting the first 7 daily doses of rFSH with a single injection of corifollitropin alfa in women undergoing ovarian stimulation for IVF/ICSI using rFSH and GnRH antagonists. Our data demonstrate that a single corifollitropin alfa injection results in an ongoing pregnancy rate which is equal to that of a daily rFSH regimen. Combined with appropriate patient selection and state-of-the-art clinical management during the stimulation phase of the treatment cycle, corifollitropin alfa potentially offers an attractive new treatment option for patients undergoing ovarian stimulation during ART.
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